Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer’s first drug candidate from its Seagen acquisition, sigvotatug vedotin, failed to meet primary endpoints in a Phase 3 nonsquamous NSCLC trial.
📍 The outcome
Pfizer’s antibody-drug conjugate **sigvotatug vedotin**, developed from its Seagen acquisition, failed to demonstrate a significant survival benefit in a phase 3 trial for advanced nonsquamous non-small cell lung cancer. The drug did not meet primary endpoints, leading to a halt in further development for this indication.
Coverage of the setback concluded without updates on alternative pathways or next steps for the compound.
Epilogue added 44d ago, after coverage quieted.
Who reported it (5)
- Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC Yahoo Finance · 47d ago
- Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 47d ago
- Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 47d ago
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 47d ago
- Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 47d ago
What happened
A Phase 3 clinical trial for sigvotatug vedotin did not demonstrate a significant improvement in overall survival for patients with advanced, pretreated nonsquamous non-small cell lung cancer (NSCLC). This candidate was among the assets Pfizer gained through its acquisition of Seagen.
Coverage from BioPharma Dive, CancerNetwork, OncLive, and Kalkine Media highlights the drug's inability to reach primary study objectives. Reporting emphasizes the setback this represents for the company’s oncology pipeline following the high-profile merger.
Future developments remain dependent on further announcements from Pfizer regarding the specific data from the trial. Coverage does not yet specify the company's next steps for the development or potential termination of the drug program.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 47d ago.
Questions people are asking
What drug failed the clinical trial?
The trial failure involved sigvotatug vedotin, an antibody-drug conjugate.
Which patient group was studied?
The trial focused on patients with advanced, pretreated nonsquamous non-small cell lung cancer (NSCLC).
What was the result of the study?
The drug did not significantly improve overall survival compared to the control metrics.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
CRISPR makes prostate cancer vulnerable to immunotherapy
CRISPR editing turns immune‑cold prostate tumors into immunotherapy targets, sparking a new treatment direction.
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy
Recent research links the thymus gland and its hormone, thymulin, to reduced age-related inflammation and improved cancer immunotherapy outcomes.
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.
Creatine supplements may help halt cancer growth, study suggests
Recent research into creatine supplements has prompted conflicting reports regarding their potential impact on cancer growth and immune response.
Leading oncologist reveals 6 habits that could promote longevity and reduce your risk of chronic illness
A leading oncologist is shifting focus from traditional wellness trends toward unconventional longevity habits, including the consumption of ice cream.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood-based mRNA diagnostic test is showing potential in identifying early-stage pancreatic cancer, a condition with historically low survival rates.